Phase 2 N=42 Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
Leiomyoma
Primary: Shrinkage of Fibroids - Size of Fibroids — -0.27; -0.18; 0.07 logcm3 — p=0.43
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
Schizophrenia and Disorders With Psychotic Features · Tobacco Use Disorder
Primary: Urinary Cotinine — 755; 1102; 1534; 1408 ng/ml
N/A N=602 Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations
Acne Vulgaris
Primary: Reduction of Inflammatory Lesions — 64.39; 63.10; 49.89 percentage reduction of lesions
Phase 2 N=1,342 Nepafenac 0.3% Two Study
Cataract
Primary: Percentage of Patients Cured at Day 14, Nepafenac 0.3% vs. Nepafenac Vehicle 0.3% — 64.6; 25.0 Percentage of patients
N/A N=74 Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Daily Urgency Incontinence Episodes — -2.5; -2.5 number of incontinence episodes/24 hours
Phase 2 N=729 Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
Influenza · Orthomyxoviruses · Myxovirus Infection
Primary: Summary of the Pre- and Post-Vaccination Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigens. — 25.9; 26.4; 26.6; 184.8 Titers
Phase 3 N=149 A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Adverse Events — 98; 10; 16 participants
Phase 4 N=38 Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
Effects of 2 Mu-opiates on Gastrointestinal Transit
Primary: Colonic Transit, Geometric Center at 24 Hours — 2.06; 2.07; 2.17 units on a scale
Early Phase 1 N=53 Dronabinol Interactions With Cognitive Enhancing Drug in Humans
Cannabis · Marijuana Abuse
Primary: CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing — 0.91; 0.9; 0.92; 0.9 units on a scale
Phase 3 N=72 Impact of Diabetes on Left Ventricular Remodeling
Diabetes
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) — 73.03; 78.06; 78.52; 79.03 ml/m^2
Phase 2 N=21 The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
Transthyretin-associated Amyloidosis With Polyneuropathy
Primary: Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6 — 94.7 percentage of participants
Phase 3 N=181 A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Exercise Endurance Time (ET) — 129.45; 13.01 Seconds — p=0.0042
N/A N=297 Blood Glucose Testing and You
Diabetes
Primary: Percent of Subjects Outside Specified Blood Glucose (BG) Range -Estimated Versus Measured Blood Glucose — 45.80 percentage of subjects
Phase 2 N=380 Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12 — 21.3; 20.2; 21.5; 20.7 Score on a scale
N/A N=553 Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis
Tinea Pedis
Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Success — 93; 88; 7 participants